Exactly, thanks for that Snoball, they rushed it to a big trial without any real evidence for clinical efficacy, (they used a surrogate endpoint, always a dangerous practice) and then bombed big time. PRR on the other hand, have established clinical efficacy first, before launching Phase II/III. This is a credit to management that they are careful with shareholders money.
- Forums
- ASX - By Stock
- IMM
- abagovomab vs oregovomab - facts ...
abagovomab vs oregovomab - facts ..., page-2
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
35.5¢ |
Change
0.015(4.41%) |
Mkt cap ! $515.6M |
Open | High | Low | Value | Volume |
34.0¢ | 36.0¢ | 34.0¢ | $1.270M | 3.611M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 286261 | 35.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.0¢ | 253490 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3250 | 0.345 |
2 | 17500 | 0.340 |
4 | 97500 | 0.330 |
2 | 33079 | 0.325 |
1 | 6234 | 0.320 |
Price($) | Vol. | No. |
---|---|---|
0.360 | 138490 | 4 |
0.365 | 64000 | 4 |
0.370 | 110306 | 3 |
0.375 | 45000 | 2 |
0.380 | 201873 | 5 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |